We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+13.07%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$87.2M
AUM Growth
+$7.34M
(+9.2%)
Cap. Flow
+$584K
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
132
New
15
Increased
19
Reduced
50
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$1.1M |
| 2 |
SNAK
Inventure Foods, Inc.
SNAK
|
+$947K |
| 3 |
VYNT
Vyant Bio, Inc. Common Stock
VYNT
|
+$929K |
| 4 |
H.B. Fuller
FUL
|
+$839K |
| 5 |
CTLP
Cantaloupe
CTLP
|
+$779K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NSPH
NANOSPHERE INC. COM NEW
NSPH
|
+$1.56M |
| 2 |
STJ
St Jude Medical
STJ
|
+$1.37M |
| 3 |
HDS
HD Supply Holdings, Inc.
HDS
|
+$1.25M |
| 4 |
Fastenal
FAST
|
+$1.22M |
| 5 |
Bank of America
BAC
|
+$675K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.45% |
| 2 | Technology | 13.15% |
| 3 | Industrials | 7.97% |
| 4 | Consumer Staples | 6.98% |
| 5 | Communication Services | 3.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$2.32B
| $5.41M | 6.2% |
673,032
-24,450
| -4% | -$196K |
|
|
STJ
2
DELISTED
St Jude Medical
STJ
| $5.2M | 5.96% |
66,673
-19,265
| -22% | -$1.37M |
|
3
Axogen
AXGN
$2.77B
| $4.35M | 4.98% |
631,908
-1,225
| -0.2% | -$6.93K |
|
4
Rockwell Medical
RMTI
$32.9M
| $3.62M | 4.15% |
4,351
+1
| +0% | +$930 |
|
5
Altimmune
ALT
$605M
| $2.11M | 2.42% |
2,880
-299
| -9% | -$205K |
|
|
CSII
6
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.05M | 2.35% |
111,600
+16,900
| +18% | +$264K |
|
7
LeMaitre Vascular
LMAT
$1.84B
| $1.97M | 2.26% |
138,358
-7,540
| -5% | -$115K |
|
|
BEAT
8
DELISTED
BioTelemetry, Inc.
BEAT
| $1.96M | 2.25% |
120,250
| – | – |
|
9
Pfizer
PFE
$159B
| $1.96M | 2.25% |
58,633
-6,377
| -10% | -$204K |
|
10
ePlus
PLUS
$2.28B
| $1.81M | 2.07% |
88,400
-4,000
| -4% | -$83.1K |
|
|
SNAK
11
DELISTED
Inventure Foods, Inc.
SNAK
| $1.56M | 1.79% |
199,750
+134,250
| +205% | +$947K |
|
12
Eli Lilly
LLY
$1.05T
| $1.55M | 1.78% |
19,700
| – | – |
|
13
IZEA Worldwide
IZEA
$53.5M
| $1.49M | 1.71% |
49,009
+13,213
| +37% | +$362K |
|
|
QUMU
14
DELISTED
Qumu Corp.
QUMU
| $1.33M | 1.53% |
300,010
+164,010
| +121% | +$732K |
|
15
Idexx Laboratories
IDXX
$43.7B
| $1.3M | 1.49% |
14,000
| – | – |
|
16
LifeVantage
LFVN
$79.7M
| $1.27M | 1.46% |
93,482
| – | – |
|
|
SVU
17
DELISTED
SUPERVALU Inc.
SVU
| $1.23M | 1.41% |
37,164
-572
| -2% | -$19.6K |
|
18
AT&T
T
$178B
| $1.21M | 1.39% |
37,154
-1,986
| -5% | -$59.1K |
|
19
AtriCure
ATRC
$2.47B
| $1.2M | 1.38% |
85,100
+900
| +1% | +$13.7K |
|
20
Altria Group
MO
$115B
| $1.2M | 1.38% |
17,400
-1,000
| -5% | -$64K |
|
21
IRIDEX
IRIX
$12.3M
| $1.2M | 1.37% |
80,800
+21,000
| +35% | +$261K |
|
|
22
Boston Scientific
BSX
$67.9B
| $1.18M | 1.36% |
+50,650
| New | +$1.1M |
|
|
VYNT
23
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $1.16M | 1.33% |
3,875
+2,642
| +214% | +$929K |
|
|
ZIXI
24
DELISTED
Zix Corporation
ZIXI
| $1.14M | 1.3% |
303,539
-5,500
| -2% | -$21.4K |
|
|
TEAR
25
DELISTED
TearLab Corporation
TEAR
| $1.12M | 1.29% |
175,524
+48,350
| +38% | +$354K |
|
Similar funds
AA
WA
AC
BCVI
SWM
HAP
RHIG
CWM
Perkins Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Perkins Capital Management held 132 positions worth $87.2M, up 9.2% from $79.9M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Perkins Capital Management's Q2 2016 filing shows 15 new, 19 increased, 50 reduced and 15 closed positions. Its largest new stake was Boston Scientific: 50,650 shares worth $1.18M. The largest sale was NANOSPHERE INC. COM NEW, an estimated $1.56M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 58% a quarter earlier, followed by Technology and Industrials.
- Perkins Capital Management's largest Q2 2016 buy was Boston Scientific: 50,650 shares worth $1.18M.
- Perkins Capital Management added most to Inventure Foods, Inc. in Q2 2016, an estimated $947K increase.
- Perkins Capital Management's biggest Q2 2016 reduction was NANOSPHERE INC. COM NEW, cutting an estimated $1.56M.
- Perkins Capital Management fully exited HD Supply Holdings, Inc. in Q2 2016, selling an estimated $1.25M.
- Perkins Capital Management's ten largest holdings make up 35% of its $87.2M portfolio in Q2 2016.
- Perkins Capital Management opened 15 new positions and closed 15 in Q2 2016.
- Perkins Capital Management's portfolio value rose 9.2% quarter-over-quarter to $87.2M.
Based on Perkins Capital Management's 13F filing for Q2 2016, filed 20 Jul 2016.